Abstract
A placebo-controlled, prospective study was undertaken to determine whether apraclonidine has an additive effect in eyes treated with timolol and pilocarpine. Twelve patients with primary open-angle glaucoma while on continuing therapy with timolol 0.5% twice daily and pilocarpine 4% four times a day in both eyes for 3 months were included in the study. A single drop of apraclonidine 1% or placebo was added to treatment with timolol and pilocarpine. Intraocular pressure (IOP) was measured on both days before a single drop of test medications in both eyes as well as 2, 4, 6, 8 and 12 h later. The fall in IOP with apraclonidine was significantly greater than with placebo at all time intervals (p < 0.05). This study suggests that apraclonidine provides an additive IOP-lowering effect to timolol and pilocarpine for at least 12 h after single-drop applications.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
Administration, Topical
-
Adrenergic alpha-Agonists / administration & dosage*
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / therapeutic use*
-
Aged
-
Clonidine / administration & dosage
-
Clonidine / analogs & derivatives*
-
Drug Synergism
-
Drug Therapy, Combination
-
Female
-
Glaucoma, Open-Angle / drug therapy*
-
Glaucoma, Open-Angle / physiopathology
-
Humans
-
Intraocular Pressure / drug effects*
-
Intraocular Pressure / physiology
-
Male
-
Middle Aged
-
Miotics / administration & dosage
-
Miotics / therapeutic use*
-
Ophthalmic Solutions
-
Pilocarpine / administration & dosage
-
Pilocarpine / therapeutic use*
-
Prospective Studies
-
Timolol / administration & dosage
-
Timolol / therapeutic use*
Substances
-
Adrenergic alpha-Agonists
-
Adrenergic beta-Antagonists
-
Miotics
-
Ophthalmic Solutions
-
Pilocarpine
-
Timolol
-
apraclonidine
-
Clonidine